Skip to main content
Dryad

Comparison of hepatosteatosis in mice treated with two forms of asparaginase: Orgel and Mittelman

Data files

Nov 27, 2024 version files 120.39 MB

Abstract

Calaspargase-pegol (SC-PEG) has replaced pegaspargase (SS-PEG) in pediatric ALL regimens in the United States. Calaspargase-pegol’s greater drug exposure has raised concern for correspondingly increased hepatotoxicity.  However, we found no difference in hepatosteatosis between formulations in obese and non-obese asparaginase-treated mice. These reassuring findings should be confirmed in clinical studies.